IgG4-related disease.
IgG4-related disease (IgG4-RD) is a relatively newly recognized fibroinflammatory condition that can affect almost any organ. It often presents as tumor-like (tumefactive) lesions that mimic cancer — pancreatic head mass, salivary gland enlargement, orbital pseudotumor, retroperitoneal fibrosis. Diagnosis requires biopsy showing IgG4+ plasma cell infiltration, storiform fibrosis, and obliterative phlebitis. Crucially: it is highly treatable. Steroids work well as induction; rituximab is the preferred steroid-sparing agent. Always biopsy before assuming cancer.
The mechanism, the cancer mimic that responds to treatment.
IgG4-RD is unique in rheumatology for how often it's initially mistaken for malignancy. Four mechanisms drive the presentation:
IgG4+ plasma cell infiltration
Dense IgG4+ plasma cell infiltration in tissue — usually with IgG4+/total IgG ratio over 40% — is the histologic hallmark. Without biopsy showing this, the diagnosis isn't secure.
Storiform fibrosis
A characteristic 'storiform' (cartwheel) pattern of fibrosis on biopsy distinguishes IgG4-RD from other causes of organ enlargement. This is one of the three histologic criteria.
Obliterative phlebitis
Inflammation that obliterates small veins (but spares arteries) is the third diagnostic histologic feature. It distinguishes IgG4-RD from vasculitis and from inflammatory mimics.
Multi-organ involvement
Pancreas (autoimmune pancreatitis type 1), salivary glands (Mikulicz syndrome), orbits, retroperitoneum (Ormond disease), kidneys, lungs, biliary tree, aorta. Most patients have more than one organ involved at diagnosis.
The 4-step plan, applied to IgG4-RD.
Get the right diagnosis
Tissue biopsy is essential — IgG4-RD is a histologic diagnosis. Serum IgG4 level is supportive but not diagnostic (about 30% of patients have normal serum IgG4). The 2019 ACR/EULAR classification criteria are the modern standard. Imaging with CT or MRI to identify all involved organs.
Learn more about labs →Clean up your food
Anti-inflammatory Mediterranean pattern. Pancreatic involvement may require enzyme replacement and a lower-fat diet during active disease.
IgG4-RD & diet →Detox your daily life
Smoking cessation. Less established for IgG4-RD specifically than for other autoimmune diseases, but general anti-inflammatory environmental work applies.
IgG4-RD & environment →Build a stronger body
Gentle exercise once disease is controlled. Resistance training preserves muscle during steroid courses.
IgG4-RD & exercise →
Go deeper.
Common misconceptions.
"This must be cancer."
IgG4-RD often presents as a tumor-like mass — pancreatic head mass, salivary gland enlargement, orbital pseudotumor — and is frequently mistaken for cancer initially. Always biopsy before committing to a cancer diagnosis when the imaging or clinical picture is atypical. IgG4-RD is highly treatable; the wrong call leads to unnecessary surgery.
"It only affects one organ."
Most IgG4-RD patients have multi-organ involvement at diagnosis. Once you find one organ, screen for others. A pancreatic mass may be the index lesion, but salivary glands, orbits, retroperitoneum, and kidneys are often involved too.
"Steroids will fix it long-term."
Steroids work well as induction therapy — but relapse rates are high after steroid taper. Rituximab is the most effective steroid-sparing agent for IgG4-RD and is increasingly first-line for severe or relapsing disease. Long-term control usually requires more than just steroids.
When to see a rheumatologist.
See a rheumatologist if you have:
- A tumor-like mass in pancreas, salivary glands, orbit, or retroperitoneum that's puzzling on imaging
- Persistent salivary gland or lacrimal gland enlargement
- Autoimmune pancreatitis
- Unexplained retroperitoneal fibrosis
- Orbital pseudotumor
- Elevated serum IgG4 level on a routine lab
- Multiple organ involvement of unclear cause
If imaging or clinical features suggest cancer but the workup is atypical, push for biopsy with IgG4 staining before committing to oncologic treatment. This is the most actionable diagnostic decision in IgG4-RD.
- Wallace ZS, et al. The 2019 American College of Rheumatology / European League Against Rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol, 2020. PubMed 31793250
- Stone JH, et al. IgG4-related disease. N Engl J Med, 2012. PubMed 22316447
- Carruthers MN, et al. Rituximab for IgG4-related disease. Ann Rheum Dis.
- Kamisawa T, et al. IgG4-related disease. Lancet, 2015. PubMed 25667017